Biologic therapies and bone loss in rheumatoid arthritis.

Biologic therapies and bone loss in rheumatoid arthritis.

Item
http://www.wikidata.org/entity/Q30243911
MicroRNA-433-3p promotes osteoblast differentiation through targeting DKK1 expressionLate conversion from tacrolimus to a belatacept-based immuno-suppression regime in kidney transplant recipients improves renal function, acid-base derangement and mineral-bone metabolism.Tocilizumab potentially prevents bone loss in patients with anticitrullinated protein antibody-positive rheumatoid arthritis.Micro-structural bone changes in early rheumatoid arthritis persist over 1-year despite use of disease modifying anti-rheumatic drug therapy.Skeletal complications of rheumatoid arthritis.Effects of denosumab on bone metabolism and bone mineral density with anti-TNF inhibitors, tocilizumab, or abatacept in osteoporosis with rheumatoid arthritis.Male patients with rheumatoid arthritis have an increased risk of osteoporosis: Frequency and risk factors.
P2860

Biologic therapies and bone loss in rheumatoid arthritis.

Item
http://www.wikidata.org/entity/Q30243911
description
2016 nî lūn-bûn
@nan
2016 թուականի Հոկտեմբերին հրատարակուած գիտական յօդուած
@hyw
2016 թվականի հոտեմբերին հրատարակված գիտական հոդված
@hy
2016年の論文
@ja
2016年論文
@yue
2016年論文
@zh-hant
2016年論文
@zh-hk
2016年論文
@zh-mo
2016年論文
@zh-tw
2016年论文
@wuu
name
Biologic therapies and bone loss in rheumatoid arthritis.
@ast
Biologic therapies and bone loss in rheumatoid arthritis.
@en
type
label
Biologic therapies and bone loss in rheumatoid arthritis.
@ast
Biologic therapies and bone loss in rheumatoid arthritis.
@en
prefLabel
Biologic therapies and bone loss in rheumatoid arthritis.
@ast
Biologic therapies and bone loss in rheumatoid arthritis.
@en
P1433
P1476
P2093
P2860
P2888
P304
P31
P356
P407
P433
P478
P50
P577
P698
P356
P1433
P1476
Biologic therapies and bone loss in rheumatoid arthritis
@en
P2093
P2860
P2888
P304
P31
P356
P407
P433
P478
P50
P577
P698